Breaking News

U.S. May Home Prices Rise 0.4% From Previous Month: FHFA
Tweet TWEET

Omeros Appoints Thomas A. Mitro as Vice President, Sales and Marketing

    Omeros Appoints Thomas A. Mitro as Vice President, Sales and Marketing

PR Newswire

SEATTLE, Nov. 29, 2012

SEATTLE, Nov. 29, 2012 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER), a
clinical-stage biopharmaceutical company committed to discovering, developing
and commercializing products targeting inflammation, coagulopathies and
disorders of the central nervous system, today announced the appointment of
Thomas A. Mitro as vice president, sales and marketing.

Mr. Mitro has over 30 years of experience in the pharmaceutical industry,
spanning sales and marketing as well as business development. Prior to
joining Omeros, Mr. Mitro served from 2002 until 2012 as vice president, sales
and marketing at ISTA Pharmaceuticals, Inc. where he oversaw the building of
ISTA's commercial infrastructure and launch of five eye care products. When
ISTA was acquired by Bausch & Lomb in June of 2012, ISTA was the third largest
branded prescription eye care business in the United States. Before ISTA, Mr.
Mitro served for over 20 years in various positions with Allergan, Inc.,
including vice president, skin care; vice president, business development; and
vice president, e-business. Mr. Mitro received his B.S. from Miami
University.

"I am excited to join Omeros' impressive management team and to help advance
the Company's products to market, starting with OMS302 for lens replacement
surgery," stated Mr. Mitro. "With two successful Phase 3 clinical trials,
Omeros has a variety of options to commercialize OMS302, including going
alone, partnering and co-promoting. I believe that OMS302 will be widely used
by ophthalmologists with the potential to generate significant revenues, and I
look forward to contributing to its commercial success."

"We are very pleased to have Tom join Omeros as we prepare to launch OMS302,"
said Gregory A. Demopulos, M.D., Omeros' chairman and chief executive officer.
"We are building an efficient commercialization strategy that can be targeted
and levered to maximize success. Tom's years of experience in eye care –
building industry-leading ophthalmic franchises – will be valuable to us as we
refine and execute our strategy to deliver on OMS302's market potential."

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering,
developing and commercializing products targeting inflammation, coagulopathies
and disorders of the central nervous system. The Company's most clinically
advanced product candidates are derived from its proprietary PharmacoSurgery™
platform designed to improve clinical outcomes of patients undergoing a wide
range of surgical and medical procedures. Omeros has four ongoing clinical
development programs. Omeros may also have the near-term capability, through
its GPCR program, to add a large number of new drug targets and their
corresponding compounds to the market. Behind its clinical candidates and GPCR
platform, Omeros is building a diverse pipeline of protein and small-molecule
preclinical programs targeting inflammation, coagulopathies and central
nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the
Private Securities Litigation Reform Act of 1995, which are subject to the
"safe harbor" created by those sections. These statements include, but are not
limited to, OMS302's rate of adoption by ophthalmologic surgeons; OMS302's
ability to generate significant revenue; the ability of OMS302's
commercialization strategy to maximize success; and that Omeros may have
capability, through its GPCR program, to add a large number of new drug
targets and their corresponding compounds to the market. Forward-looking
statements are based on management's beliefs and assumptions and on
information available to management only as of the date of this press release.
Omeros' actual results could differ materially from those anticipated in these
forward-looking statements for many reasons, including, without limitation,
the risks, uncertainties and other factors described under the heading "Risk
Factors" in the Company's Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on November 9, 2012. Given these risks,
uncertainties and other factors, you should not place undue reliance on these
forward-looking statements, and the Company assumes no obligation to update
these forward-looking statements publicly, even if new information becomes
available in the future.

SOURCE Omeros Corporation

Contact: Jennifer Cook Williams, Cook Williams Communications, Inc., Investor
and Media Relations, +1-360-668-3701, jennifer@cwcomm.org